Assessment of immune receptor involvement in cancer through in silico comparison of immune lectin ligands and cancer glycosylation

Abstract

Siglec-15 is upregulated on various tumor tissues, with varying expression levels and this may lead to different prognosis. However, Siglec-15 expressed normally on macrophage, we found that in bladder cancer the T cells markers are negatively correlated with siglec-15 as well as PD-1. Suggesting that siglec-15 may a potential target therapy on bladder by blocking the siglec-15 pathway. A further study for CD44 interaction with Siglec-15 on tumor is needed. Moreover, understanding of the biochemical structure for Siglec-15 and using the biochemical tool to investigate the unknown ligand on T cells would be helpful to understand how it can bind on tumor site.